179 related articles for article (PubMed ID: 26182876)
1. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
Szebeni J; Storm G
Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
[TBL] [Abstract][Full Text] [Related]
2. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
Szebeni J; Muggia F; Gabizon A; Barenholz Y
Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
[TBL] [Abstract][Full Text] [Related]
3. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
[TBL] [Abstract][Full Text] [Related]
4. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
[TBL] [Abstract][Full Text] [Related]
5. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
[TBL] [Abstract][Full Text] [Related]
6. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
Szebeni J
Toxicology; 2005 Dec; 216(2-3):106-21. PubMed ID: 16140450
[TBL] [Abstract][Full Text] [Related]
7. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
8. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals.
Szebeni J
Mol Immunol; 2014 Oct; 61(2):163-73. PubMed ID: 25124145
[TBL] [Abstract][Full Text] [Related]
9. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
[TBL] [Abstract][Full Text] [Related]
10. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
[TBL] [Abstract][Full Text] [Related]
11. The interaction of liposomes with the complement system.
Szebeni J
Crit Rev Ther Drug Carrier Syst; 1998; 15(1):57-88. PubMed ID: 9523086
[TBL] [Abstract][Full Text] [Related]
12. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro.
Mészáros T; Csincsi ÁI; Uzonyi B; Hebecker M; Fülöp TG; Erdei A; Szebeni J; Józsi M
Nanomedicine; 2016 May; 12(4):1023-1031. PubMed ID: 26733258
[TBL] [Abstract][Full Text] [Related]
13. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model.
Szebeni J; Bedőcs P; Urbanics R; Bünger R; Rosivall L; Tóth M; Barenholz Y
J Control Release; 2012 Jun; 160(2):382-7. PubMed ID: 22421426
[TBL] [Abstract][Full Text] [Related]
14. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
[TBL] [Abstract][Full Text] [Related]
15. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
[TBL] [Abstract][Full Text] [Related]
17. Liposome-mediated triggering of complement cascade.
Moghimi SM; Hamad I
J Liposome Res; 2008; 18(3):195-209. PubMed ID: 18720195
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
[TBL] [Abstract][Full Text] [Related]
19. Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information.
Fülöp T; Nemes R; Mészáros T; Urbanics R; Kok RJ; Jackman JA; Cho NJ; Storm G; Szebeni J
J Control Release; 2018 Jan; 270():268-274. PubMed ID: 29203414
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Szebeni J
Drug Discov Today; 2018 Mar; 23(3):487-492. PubMed ID: 29326077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
